Tagged with Regulatory Reform,

Mexico Earlier in 2020, PharmaBoardroom sat down with several key stakeholders in the Mexican healthcare and life sciences industry, from the leaders of multinational affiliates, start-up entrepreneurs, association heads, and key opinion leaders. Here, we round up three of their most talked about topics.   Government  One of the most talked-about…

Cyprus Healthcare and life science industry advisory services head at KPMG Cyprus, Iacovos Ghalanos, discusses the challenge of implementing the National Health Insurance Scheme, pricing pressures and how their innovative services help companies manage this crucial trend. Ghalanos also touches on the need for greater collaboration between the public and private…

Turkey Dr. Hakkı Gürsöz, president of the Turkish Medicines and Medical Devices Agency (TiTCK), provides insights into recent localization and pricing policies and delivers strong messages to both domestic and foreign companies operating in Turkey while underlining TiTCK’s ambitions to work hand-in-hand with the industry, the world’s most respected regulatory authorities…

Hong Kong Professor Justin Wu, chief operating officer of the Chinese University of Hong Kong (CUHK) Medical Center, shares his professional background and interest in gastroenterology, his insights into the research and commercialization environment in Hong Kong, and his hope for government, industry and academia to work together to propel Hong Kong…

India Dr. Letitia Robinson, Director of the US FDA India Office, provides insights into the main goals and responsibilities of the FDA in India and documents the US FDA’s collaboration efforts with its Indian regulatory counterparts. Could you introduce to our international readers the US FDA’s Office of International Programs and…

Spain Santiago de Quiroga, president editor of leading Spanish pharmaceutical industry newspaper El Global and CEO of healthcare communications group WeCare-u, discusses the country’s health priorities, highlighting the upcoming Personalized Medicine Plan that the government will issue by the end of 2018 and predicts how regulators are going to find new…

Pharma While drug developers, healthcare practitioners and patients all rejoice at the advent of a golden age of scientific advancement in medicine – symbolized by recent radical breakthroughs in all manners of domains from stem cells and CAR-T generation immunotherapy to gene tech and 3D bio-printing – it is clear that…

Portugal Heitor Costa, Executive Director for APIFARMA, the Portuguese Pharmaceutical Industry Association, outlines the recent improvements in industry and governmental agreements, the importance of non-prescription medicines, and raising societal awareness on the strengths of OTC medicines. While touching on pertinent topics that affect the entire pharmaceutical production value chain, Costa highlights…

Portugal ARSLVT exists to make sure that people living in the Lisbon and Tagus Valley have access to quality health care, adapting the resources available to the region’s health needs and complying with and enforcing the National Health Plan. Luis Pisco is confident in Portugal’s development as a healthy nation, and…

Latvia Anda Čakša, Latvia’s minister of health since 2016, discusses her current priorities, regulatory reform, areas of strengths and weaknesses in the nation’s healthcare infrastructure, e-health, and combating the threat of non-communicable diseases. What have been your main achievements since assuming position as health minister back in 2016? “The e-health system…

Ecuador Hector Enriquez, general manager of Laboratorios Industriales Farmaceuticos Ecuadorianos (LIFE), details the flagship Ecuadorian pharmaceutical company’s focus on developing its own market-relevant formulations and the implementation of international manufacturing standards to compete with international pharmaceutical companies in Ecuador. Could you present LIFE Laboratories’ activities and most recent developments in Ecuador?…

Baltics Rauls Velins, Roche’s general manager for Latvia, introduces the company’s longstanding commitment to the Latvian market, Roche’s role in helping facilitate Latvia’s new National Cancer Plan, and the potential for personalized medicine across the Baltics. Could you please start by introducing Roche in Latvia and the strategic significance of the…